ClinicalTrials.gg
RecruitingNCT06350617Updated Apr 28, 2026

Personalized rTMS Protocol Based on Functional Reserve to Enhance Ambulatory Function in PD Patients

An interventional study of High-Frequency, ipsilateral M1 and High-Frequency, bilateral M1 in Parkinson's Disease and Parkinsonism, sponsored by Samsung Medical Center. Recruiting at 1 site in South Korea. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Samsung Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Parkinson Disease with a site in Korea, Republic of — 13 open to participants now, 15 under way, 1 of them phase 3. Parkinson Disease · Korea, Republic of.

Planned enrollment
33rd of 67
60 · median 60
Started
2024
with 2 others
No phase
28 of 76
6 open now
Primary completion
2026-09
later than 2 of 14 live
Registered
64th of 76
by date

Among the 76 studies in Parkinson Disease with a site in Korea, Republic of, this one is the 33rd largest by planned enrollment of the 67 interventional ones that give a count, is one of 3 that started in 2024, is one of 28 with no phase, reaches primary completion later than 2 of the 14 other live ones, and was the 64th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

13 of the 76 studies in Parkinson Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Parkinson Disease with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The objective of this study was to determine the effects of protocols of repetitive transcranial magnetic stimulation (rTMS) therapy based on the functional reserve of each patient with Parkinson's disease, compared to conventional high-frequency rTMS therapy on bilateral primary motor cortex (M1). Investigators hypothesized that the functional reserve of each patient with Parkinson's disease will be different, and therefore an appropriate simulating target for rTMS therapy is needed. In addition, this approach could be more effective compared to conventional protocols applied to patient with Parkinson's disease regardless of their severity, predicted mechanism of motor function recovery, or functional reserves.

Read the detailed description

rTMS treatment for patients with Parkinson's disease is traditionally based on stimulating the neural network of brain. The widely-used traditional rTMS treatment protocol involves high-frequency stimulation over the bilateral primary motor cortex (M1) to enhance motor and gait functions. However, concerns have arisen regarding the effect of rTMS on motor recovery in patients with Parkinson's disease. Although still subject to debate, a possible reason for the diverse results of rTMS applied is the uniform application protocol to individuals with varying pathologies and functional reserves, aimed at enhancing recovery.

Therefore, this study was aimed to determine the effects of protocols of rTMS therapy based on the functional reserve of each patient with Parkinson's disease.

Based on screening evaluations (Timed Up and Go Test (TUG), Timed Up and Go Dual Task-Cognitive (TUG-Cog)), investigators hypothesized that patients could be categorized into two groups: 1) priority in motor functional reserve, 2) priority in cognitive functional reserve. For each group, investigators plan to randomly assign patients to experimental and control groups to demonstrate the efficacy of different rTMS protocols based on functional reserves compared to conventional high-frequency rTMS applied to the bilateral M1.

03

Conditions studied

  • Parkinson's Disease and Parkinsonism

Keywords

  • Parkinson's Disease
  • rTMS
  • Functional reserve
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. patients with Parkinson's disease, diagnosed by the United Kingdom (UK) Parkinson's Disease Society Brain Bank Diagnostic Criteria,
  2. Modified Hoehn and Yahr (H\&Y) scale, stage 2\~4,
  3. patients who can walk on flat surfaces without the need for a gait aid,
  4. aged ≥50 years old,
  5. patients willing to sign the .

Exclusion criteria

Exclusion Criteria:

  1. those with to rTMS, such as epilepsy, implanted metal objects in the head, or a history of craniotomy,
  2. those with cognitive impairment, confirmed through the (MoCA) test as follows: \< 7 points: Illiterate \< 13 points: Education duration 0.5-3 years \< 16 points: Education duration 4-6 years \< 19 points: Education duration 7-9 years \< 20 points: Education duration 10 years or more
  3. those with coexisting neurological conditions, such as spinal cord injury or Stroke,
  4. those with major psychiatric disorders, such as major depression, schizophrenia, or dementia,
  5. those with severe on-off phenomena or severe dyskinesia, deemed by the investigators to render participation in the study inappropriate.
  6. those having contraindications to conduct an MRI study,
  7. those who are pregnant or lactating,
  8. patients who have refused to participate in this study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Ipsilateral High-Frequency

    Patients with motor priority confirmed by TUG and TUG-Cog tests. High-frequency (HF) rTMS over more affected primary motor cortex (M1) of lower extremity will be applied.

    Device: High-Frequency, ipsilateral M1

  • Active comparator
    Bilateral High-Frequency1

    Patients with motor priority confirmed by TUG and TUG-Cog tests. High-frequency (HF) rTMS over bilateral M1 of lower extremities will be applied.

    Device: High-Frequency, bilateral M1

  • Experimental
    DLPFC High-Frequency

    Patients with cognitive priority confirmed by TUG and TUG-Cog tests. High-frequency (HF) rTMS over Lt. dorsolateral prefrontal cortex (DLPFC) will be applied.

    Device: High-Frequency, Lt. DLPFC

  • Active comparator
    Bilateral High-Frequency2

    Patients with cognitive priority confirmed by TUG and TUG-Cog tests. High-frequency (HF) rTMS over bilateral M1 of lower extremities will be applied.

    Device: High-Frequency, bilateral M1

Interventions

  • DeviceHigh-Frequency, ipsilateral M1

    rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses. rTMS target: ipsilateral primary motor cortex of lower extremity. Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions. Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease.

  • DeviceHigh-Frequency, bilateral M1

    rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses. rTMS target: bilateral primary motor cortex of lower extremity. Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions. Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease.

  • DeviceHigh-Frequency, Lt. DLPFC

    rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses. rTMS target: Lt. DLPFC Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions. Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease.

  • DeviceHigh-Frequency, bilateral M1

    rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses. rTMS target: bilateral primary motor cortex of lower extremity. Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions. Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease.

06

What researchers measure

Primary outcomes

  1. Differences of Timed Up and Go Test (TUG)

    Measurement for gait function.

    Time frame: From baseline T0 to Post-intervention T2 (4 weeks)

Secondary outcomes

  1. Differences of Timed Up and Go Test (TUG)

    Measurement for gait function.

    Time frame: From baseline T0 to During-intervention T1 (2 weeks)

  2. Differences of Timed Up and Go Test (TUG)

    Measurement for gait function.

    Time frame: From baseline T0 to Follow-up T3 (2 months)

  3. Differences of Timed Up and Go Test-Cognitive (TUG-Cog)

    Measurement for gait and cognitive function.

    Time frame: From baseline T0 to During-intervention T1 (2 weeks)

  4. Differences of Timed Up and Go Test-Cognitive (TUG-Cog)

    Measurement for gait and cognitive function.

    Time frame: From baseline T0 to Post-intervention T2 (4 weeks)

  5. Differences of Timed Up and Go Test-Cognitive (TUG-Cog)

    Measurement for gait and cognitive function.

    Time frame: From baseline T0 to Follow-up T3 (2 months)

  6. Differences of Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Part III

    Measurement for motor function of patients with Parkinson's disease. Score ranges from 0 to 132; higher score indicates more severity of disease status

    Time frame: From baseline T0 to Post-intervention T2 (4 weeks)

  7. Differences of MDS-UPDRS, Part III

    Measurement for motor function of patients with Parkinson's disease. Score ranges from 0 to 132; higher score indicates more severity of disease status

    Time frame: From baseline T0 to Follow-up T3 (2 months)

  8. Differences of New Freezing of Gait Questionnaire (FoG-Q)

    Measurement for gait function of patients with Parkinson's disease Score ranges from 0 to 28; higher score indicates more severity of disease status

    Time frame: From baseline T0 to Post-intervention T2 (4 weeks)

  9. Differences of New Freezing of Gait Questionnaire (FoG-Q)

    Measurement for gait function of patients with Parkinson's disease Score ranges from 0 to 28; higher score indicates more severity of disease status

    Time frame: From baseline T0 to Follow-up T3 (2 months)

  10. Differences of Digit span Test

    Measurement for cognitive function

    Time frame: From baseline T0 to Post-intervention T2 (4 weeks)

  11. Differences of Digit span Test

    Measurement for cognitive function

    Time frame: From baseline T0 to Follow-up T3 (2 months)

  12. Differences of Trail making Test

    Measurement for cognitive function

    Time frame: From baseline T0 to Post-intervention T2 (4 weeks)

  13. Differences of Trail making Test

    Measurement for cognitive function

    Time frame: From baseline T0 to Follow-up T3 (2 months)

  14. Differences of Gait lab parameter (Gait speed)

    Measurement for gait function. Gait speed (km/hr) will be measured

    Time frame: From baseline T0 to Post-intervention T2 (4 weeks)

  15. Differences of Gait lab parameter (Gait speed)

    Measurement for gait function. unit: km/hr Gait speed (km/hr) will be measured

    Time frame: From baseline T0 to Follow-up T3 (2 months)

  16. Differences of Gait lab parameter (Stride length)

    Measurement for gait function Stride length (m) will be measured

    Time frame: From baseline T0 to Post-intervention T2 (4 weeks)

  17. Differences of Gait lab parameter (Stride length)

    Measurement for gait function Stride length (m) will be measured

    Time frame: From baseline T0 to Follow-up T3 (2 months)

  18. Differences of Gait lab parameter (Step count)

    Measurement for gait function Step count will be measured

    Time frame: From baseline T0 to Post-intervention T2 (4 weeks)

  19. Differences of Gait lab parameter (Step count)

    Measurement for gait function Step count will be measured

    Time frame: From baseline T0 to Follow-up T3 (2 months)

  20. Differences of Gait lab parameter (Cadence)

    Measurement for gait function Cadence (step count/min) will be measured

    Time frame: From baseline T0 to Post-intervention T2 (4 weeks)

  21. Differences of Gait lab parameter (Cadence)

    Measurement for gait function Cadence (step count/min) will be measured

    Time frame: From baseline T0 to Follow-up T3 (2 months)

  22. Differences of Gait lab parameter (Swing ratio)

    Measurement for gait function Swing ratio (% of swing phase of 1 gait cycle) will be measured

    Time frame: From baseline T0 to Post-intervention T2 (4 weeks)

  23. Differences of Gait lab parameter (Swing ratio)

    Measurement for gait function Swing ratio (% of swing phase of 1 gait cycle) will be measured

    Time frame: From baseline T0 to Follow-up T3 (2 months)

  24. Differences of Gait lab parameter (Stride time)

    Measurement for gait function Stride time (unit- second, time from heel strike to next heel strike) will be measured

    Time frame: From baseline T0 to Post-intervention T2 (4 weeks)

  25. Differences of Gait lab parameter (Stride time)

    Measurement for gait function Stride time (unit- second, time from heel strike to next heel strike) will be measured

    Time frame: From baseline T0 to Follow-up T3 (2 months)

  26. Differences of Gait lab parameter (Pressure distribution)

    Measurement for gait function Pressure distribution (unit - pecentage, pressure distribution among heel, mild, and toe) will be measured

    Time frame: From baseline T0 to Post-intervention T2 (4 weeks)

  27. Differences of Gait lab parameter (Pressure distribution)

    Measurement for gait function Pressure distribution (unit - pecentage, pressure distribution among heel, mild, and toe) will be measured

    Time frame: From baseline T0 to Follow-up T3 (2 months)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Yun SJ, Lee HS, Kim DH, Im S, Yoo YJ, Kim NY, Lee J, Kim D, Park HY, Yoon MJ, Kim YS, Chang WH, Seo HG. Efficacy of personalized repetitive transcranial magnetic stimulation based on functional reserve to enhance ambulatory function in patients with Parkinson's disease: study protocol for a randomized controlled trial. Trials. 2024 Aug 16;25(1):543. doi: 10.1186/s13063-024-08385-2. PubMed 39152467 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Sep 2026, 31 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 31 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2024
First posted
Apr 5, 2024
StartActual
Feb 20, 2024
Primary completionEst.
Sep 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06350617
Collaborators
National Research Foundation of Korea, Ministry of Food and Drug Safety, Korea, Seoul National University Hospital, Bucheon St. Mary's Hospital, Saint Vincent's Hospital, Korea, Severance Hospital, Kumoh National Institute of Technology, NEUROPHET
Responsible party
Won Hyuk Chang (Professor, Samsung Medical Center) — Principal investigator
First posted
Apr 5, 2024
Start date
Feb 20, 2024
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Apr 28, 2026

Study contacts

Won Hyuk Chang, PhD
Contact
wh.chang@samsung.com
+82-2-3410-6068
Ho Seok Lee, PhD
Contact
hoseok89.lee@samsung.com
+82-2-3410-2810
Won Hyuk Chang, PhD
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion